Adalimumab for sight-threatening uveitis in Behçet's disease.
about
Emerging drugs for uveitisA Clinical Picture of the Visual Outcome in Adamantiades-Behçet's DiseaseAdalimumab in the management of Behçet's diseaseBehçet's Uveitis.Current approach in the diagnosis and management of panuveitis.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Review of Systemic Immunosuppression for Autoimmune UveitisNew Evidence-Based Treatment Approach in Behçet's Disease.Aqueous Humor Levels of Different Interleukins 1-β, 2, 6 and 10, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab.Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsAdalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Adalimumab in dermatologyManaging Behçet's disease: An update on current and emerging treatment options.Pharmacotherapy of scleritis: current paradigms and future directions.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Update on the therapy of Behçet disease.Pharmacotherapy of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Adalimumab (humira™) in ophthalmology: a review of the literature.Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.Biological agents for the treatment of uveitis.Biologic agents in inflammatory eye disease.Adalimumab for the treatment of Behçet's disease: experience in 19 patients.The role of biologic agents in the management of non-infectious uveitis.Systemic treatment of vitreous inflammation.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Current and future treatments for Behçet's uveitis: road to remission.Approaches to immunosuppression in Behçet's disease.Systemic treatments for noninfectious vitreous inflammation.Therapy of ocular Behçet disease.Ocular Involvement of Behçet's Syndrome: a Comprehensive Review.New pharmacotherapy options for noninfectious posterior uveitis.The Use of Biologic Therapies in Uveitis.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.Use of biologic agents in ocular manifestations of rheumatic disease.Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease.
P2860
Q24630848-F4B0ECD2-80B7-4760-A5F9-66DBEAB73594Q26777598-0AA98F35-10FD-4962-9618-6FC54DF353DAQ26861428-4856589D-7D9F-4E9C-A3A8-FEF7738E781DQ33559788-BCEF67BB-82B3-4A43-AC64-73BB03B4AA3FQ33737954-1EDFC7C0-E685-40CD-BCAB-B711A4418430Q33910781-2901B6F3-FE72-40B7-9BBD-48F68297404BQ34220221-218BC739-B770-4606-BB3C-22E2C66AB3CDQ34627012-DFC0CD7F-76CE-4DC9-A689-7BB6E31A2D7FQ35295186-DFE21D5B-1DE5-407D-8D64-8C70D114E35CQ35584483-9D73393A-9351-46F7-B549-C35527C7B52AQ35699360-3F8BA355-FE22-4093-BE56-27281DF148F3Q36846629-F760B773-8BC0-40DF-B95C-660B0718501AQ37105146-EE29BEC2-46E0-4903-B981-EABF3B7A6E76Q37142425-2FB7D860-4BA3-46D1-A8D4-009127B29D19Q37230348-F49BD9A8-DA10-4C50-96AF-B2051850A8A8Q37466204-1A5B5F96-50D3-4C7C-BBE3-C82358CD2CFBQ37600483-91AB84FA-F80F-4644-A3DE-F3D9DD860F4FQ37650221-9F5802E8-AE7A-46AE-BD7B-1EF986D6D6BCQ37712230-7F523FFA-3605-4140-A54D-89A789B3D8C2Q37724245-74B21B2A-E461-46FB-A743-17E0B468D584Q37756167-AC7ABC7F-6BF0-4FDF-9F9B-37B489F456ACQ37823308-86208B23-E1A8-4060-89DF-A97D2A05EA19Q37834466-F06029A4-A167-4286-BB7F-DA38E817C783Q37984565-73A9D806-D191-49FF-83D0-6C3F3B998072Q37997772-F84CBD1B-7601-40B1-9032-3919D870BCEAQ38020828-A91CDB76-21D7-4662-B4CC-AD0505336A36Q38025152-8DB8088F-990B-4DFA-8E0A-F9685FE8862DQ38048774-4609DC16-ED25-466E-9582-9F6BE87CEAC6Q38074446-0E87DFE4-EB05-4F0D-A9F9-C5BEDB29A3EAQ38111308-6F7E9504-E404-4326-865C-8536F26A2482Q38119551-97B1AEA1-B853-49DE-98B7-E4A7B0A886FDQ38172090-2C14E793-319D-41A8-9932-5D817B9EB40DQ38174652-148DDA23-2293-43E7-BDED-E7B32777912FQ38211813-673EAFDD-1D2C-4110-8E19-1316065F29E3Q38253095-F9624B0F-5AFB-4A8E-B5E9-E862B5405857Q38272248-523C0000-9761-4E0A-92C2-BE2A05A4BC1FQ38773144-2B598372-2366-4162-A1DD-4FC95AE28B42Q39181648-D87EDDBD-6847-4B8C-A6A3-68E09572C7A4Q40008319-367B680E-5463-4BB8-8E96-2E2A1617AF44Q41265511-5DDF530D-BF35-4CE4-A1A2-21AB2FFFEB1B
P2860
Adalimumab for sight-threatening uveitis in Behçet's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Adalimumab for sight-threatening uveitis in Behçet's disease.
@ast
Adalimumab for sight-threatening uveitis in Behçet's disease.
@en
type
label
Adalimumab for sight-threatening uveitis in Behçet's disease.
@ast
Adalimumab for sight-threatening uveitis in Behçet's disease.
@en
prefLabel
Adalimumab for sight-threatening uveitis in Behçet's disease.
@ast
Adalimumab for sight-threatening uveitis in Behçet's disease.
@en
P2093
P2860
P921
P356
P1433
P1476
Adalimumab for sight-threatening uveitis in Behçet's disease
@en
P2093
R D Situnayake
P2860
P2888
P304
P356
10.1038/SJ.EYE.6702352
P577
2006-04-07T00:00:00Z